Swissmedic Grants Approval for a Clinical Study of Neovacs SA's TNFa-kinoid Candidate for the Treatment of Crohn's Disease

Paris, June 2, 2009 - Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, today announced that Swissmedic (the Swiss regulatory authority for medicinal products) has granted clearance for the clinical study of its TNFa-kinoid candidate in patients with moderate-to-severe Crohn’s disease. The TNFa-kinoid is currently being evaluated in a Phase I/II clinical study in South Africa. Following the receipt of Swissmedic’s consent, Neovacs now plans to add two Swiss sites to the ongoing trial during the month of June.